Array Biopharma Reports Results of Triplet Combination Therapy in P-III BEACON CRC Trial for BRAF-Mutant Metastatic Colorectal Cancer (mCRC)

 Array Biopharma Reports Results of Triplet Combination Therapy in P-III BEACON CRC Trial for BRAF-Mutant Metastatic Colorectal Cancer (mCRC)

Array Biopharma Reports Results of Triplet Combination Therapy in P-III BEACON CRC Trial for BRAF-Mutant Metastatic Colorectal Cancer (mCRC)

Shots:
  • The safety lead-in P-III BEACON CRC study involves assessing of a triplet combination Braftovi (encorafenib), Mektovi (binimetinib) & Erbitux (cetuximab) in patients with BRAF mutant mCRC
  • P-III BEACON CRC trial results: mOS 15.3 mos.; mPFS 8 mos.; ORR 48%; well-tolerated with no toxicities, will be presented at ASCO 2019
  • Braftovi (encorafenib), Mektovi (binimetinib), Erbitux (cetuximab) is a BRAF inhibitor, a MEK inhibitor and an anti-EGFR Ab respectively. On 7 Aug, 2018 Braftovi received FDA’s BT designation in combination with Mektovi & Erbitux for patients with 2L BRAF mutant mCR

Click here to read full press release/ article | Ref:  Array Biopharma Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post